1. Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial. Issue 11 (23rd July 2019) Authors: Kansal, A.; Reifsnider, O. S.; Proskorovsky, I.; Zheng, Y.; Pfarr, E.; George, J. T.; Kandaswamy, P.; Ruffolo, A. Journal: Diabetic medicine Issue: Volume 36:Issue 11(2019) Page Start: 1494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial1. Issue 11 (23rd July 2019) Authors: Kansal, A.; Reifsnider, O. S.; Proskorovsky, I.; Zheng, Y.; Pfarr, E.; George, J. T.; Kandaswamy, P.; Ruffolo, A. Journal: Diabetic medicine Issue: Volume 36:Issue 11(2019) Page Start: 1494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗